Neos Therapeutics (NEOS) Reports In-Line Q2 EPS

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. SWKS
7. ANET
8. SPY
9. XYZ
10. CVS

Go back to Neos Therapeutics (NEOS) Reports In-Line Q2 EPS

Neos Therapeutics Reports Second Quarter 2017 Financial Results

August 8, 2017 7:00 AM EDT

DALLAS and FORT WORTH, Texas, Aug. 08, 2017 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release (XR) products using its proprietary modified-release drug delivery and orally disintegrating tablet (ODT) technologies, today reported financial results for the second quarter ended June 30, 2017 and provided a business update.

We are very excited about the recent FDA approval of Cotempla XR-ODT. As we prepare for the launch this fall, we will be able to leverage our existing sales force and commercial... More